Zealand University Hospital

Running trials

• Not yet recruiting

  Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy

  NCT07842198· Phase 2· Zealand University Hospital· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Not yet recruiting

  Speech-Based Artificial Intelligence for Detection of Dementia in Danish Patients (DetectAI)

  NCT07200739· Zealand University Hospital· Source

• Not yet recruiting

  Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies

  NCT07878208· Odense University Hospital· Source

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· CSL Behring· Source

• Not yet recruiting

  REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors

  NCT07762820· Ludwig-Maximilians - University of Munich· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)

  2025-524894-17-00· Phase 2/3· Eyebiotech Limited· Source

• Not yet recruiting

  Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer

  NCT07409844· Phase 2· Ismail Gögenur· Source

• Recruiting

  Assessment of Residual Congestion in Acute Decompensated Heart Failure

  NCT07682298· Aarhus University Hospital· Source

• Recruiting

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  2025-520982-39-00· Phase 3· Universita Degli Studi Di Milano Bicocca· Source

• Recruiting

  Effects of Exercise and Sleep on Motor Learning and Functional Abilities in Multiple Sclerosis

  NCT07304375· Zealand University Hospital· Source

• Recruiting

  The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract

  NCT07077447· Zealand University Hospital· Source

• Enrolling by invitation

  Optical Coherence Tomography in Acute Vessel Evaluation

  NCT07422688· Aarhus University Hospital Skejby· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  Online Personalized Psychological Intervention for Patients With Heart Disease and Depression or Anxiety (MY-CHOICE)

  NCT07569458· University of Southern Denmark· Source

• Recruiting

  Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps

  NCT07187583· Phase 4· Copenhagen University Hospital, Rigshospitalet· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer

  NCT06781879· Phase 4· Jakob Kristian Jakobsen· Source

• Active, not recruiting

  Tapering of biologics in chronic rhinosinusitis with nasal polyps

  2024-519758-35-01· Phase 4· Rigshospitalet· Source

• Recruiting

  Randomized Controlled Trial of the Effects of Combined Resistance and AerobiC Exercise on Health-related Quality of Life in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer (REACH)

  NCT06938971· Copenhagen University Hospital, Rigshospitalet· Source

• Active, not recruiting

  Complete remission study

  2024-519628-25-00· Phase 4· Rigshospitalet· Source

• Enrolling by invitation

  Reducing Sedentary Behavior in Patients with Severe COPD: a Feasibility Study on Nurse-Led Motivational Intervention

  NCT06882863· Zealand University Hospital· Source

• Recruiting

  Thrombolysis in Factor Xa-inhibitors Trial

  NCT06878066· Phase 3· Guri Hagberg· Source

• Enrolling by invitation

  Sarcopenia and Cachexia in Patients With Lung Cancer

  NCT06730685· Zealand University Hospital· Source

• Active, not recruiting

  Continuous Glucose Monitoring in Dialysis Patients With Diabetes

  NCT06641765· Bo Feldt-Rasmussen· Source

• Recruiting

  A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record

  NCT06642272· Phase 4· Herlev and Gentofte Hospital· Source

• Active, not recruiting

  A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

  NCT06559163· Phase 2· Zenas BioPharma (USA), LLC· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure

  NCT06560047· Aalborg University Hospital· Source

• Recruiting

  New treatments to reduce cardiovascular disease in type 1 diabetes

  2023-505794-32-04· Phase 3· Steno Diabetes Center Copenhagen· Source

• Recruiting

  Danish Pragmatic Randomized Trial to Evaluate the Effect of HeartLogic-Guided Management on Heart Failure Outcomes

  NCT06099158· Tor Biering-Sørensen· Source

• Enrolling by invitation

  Improving Genomic Profiling and Reducing Time to Cancer Treatment Via Targeted Use of Endoscopic Ultrasound

  NCT06848738· Zealand University Hospital· Source

• Active, not recruiting

  Examining the impact of propranolol on preoperative anxiety and on tumorigenic changes in patients with pancreatic ductal adenocarcinomas: a randomized, triple-blinded, placebo-controlled pilot trial (The IMPULS trial)

  2023-506553-37-00· Phase 2· Zealand University Hospital· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Janssen Research & Development, LLC· Source

• Enrolling by invitation

  Physical Attendance Versus Telephone or Video Follow-up in Patients With Non-functioning Pituitary Tumors.

  NCT06297473· Zealand University Hospital· Source

• Recruiting

  STRONG for Surgery & Strong for Life - Intensive Prehabilitation for Risk Reduction in Ventral Hernia Repair

  NCT06611462· Bispebjerg Hospital· Source

• Active, not recruiting

  Risk Factors, Incidence, and Progression of Lymphedema Among Men With Prostate Cancer. The AWARE Cohort

  NCT07607431· Copenhagen University Hospital, Rigshospitalet· Source

• Active, not recruiting

  Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

  NCT05890729· Phase 1/2· Xentria, Inc.· Source

• Recruiting

  Coronary Computed Tomography Versus Invasive Angiography for Non-ST Elevation Acute Coronary Syndrome

  NCT06101862· Copenhagen University Hospital, Rigshospitalet· Source

• Active, not recruiting

  A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  NCT05936359· Phase 1· Incyte Corporation· Source

• Active, not recruiting

  Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841)

  2022-500100-21-01· Phase 2· Oslo University Hospital Hf· Source

• Recruiting

  Does peri-operative treatment with Tranexamic Acid reduce the early relapse rate for patients with melanoma; a randomised controlled trial

  2022-502633-26-00· Phase 3· Aarhus University Hospital· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

  NCT05878769· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

  NCT05636176· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  The "SPARCOL" Study

  NCT05734300· Zealand University Hospital· Source

• Active, not recruiting

  The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

  NCT03129490· Phase 4· Herlev and Gentofte Hospital· Source

• Active, not recruiting

  The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

  NCT03129555· Phase 4· Herlev and Gentofte Hospital· Source

• Active, not recruiting

  A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT05578976· Phase 3· Genmab· Source

Showing 50 of 79.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer6 recruiting
• Coronary artery disease6 recruiting
• Chronic kidney disease5 recruiting
• Heart failure5 recruiting
• Lung cancer5 recruiting
• Atrial fibrillation4 recruiting
• Bladder cancer4 recruiting
• Multiple myeloma4 recruiting
• Childhood cancers3 recruiting
• Kidney cancer3 recruiting
• Stroke3 recruiting
• Type 2 diabetes3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukaemia2 recruiting
• Alzheimer disease2 recruiting
• COPD2 recruiting
• Sarcoidosis2 recruiting
• Cervical cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic rhinosinusitis with nasal polyps1 recruiting
• Depression1 recruiting
• Frontotemporal dementia1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Lewy body dementia1 recruiting
• Macular degeneration1 recruiting
• Melanoma1 recruiting
• Mild cognitive impairment1 recruiting
• Multiple sclerosis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Pituitary tumours1 recruiting
• Type 1 diabetes1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Completed

  A Precision Medicine Approach to the Prevention of Depression in Patients With Atrial Fibrillation

  NCT07178691· University of Southern Denmark· Source

• Withdrawn

  A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration

  NCT05126966· Phase 3· Hoffmann-La Roche· Source

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Novo Nordisk A/S· Source

• Completed

  Intratumoral Flu Vaccine and Pembrolizumab in Colorectal Cancer

  2023-503228-17-00· Phase 2· Zealand University Hospital· Source

• Active, not recruiting

  Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE

  2022-502105-15-00· Phase 2· Alumis Inc.· Source

• Completed

  Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  2022-502196-31-00· Phase 2/3· Kartos Therapeutics Inc.· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Shionogi· Source

• Completed

  A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

  NCT05849922· Phase 2· Sanofi· Source

• Completed

  Implementation of SGLT-2 Inhibitors in Patients With Heart Failure Through a New Digital Strategy

  NCT05890131· Morten Schou· Source

• Active, not recruiting

  A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps

  NCT05942222· Phase 4· Copenhagen University Hospital, Rigshospitalet· Source

• Completed

  Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

  NCT05819398· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· Phase 3· AstraZeneca· Source

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

  NCT05620836· Phase 3· Incyte Corporation· Source

• Completed

  Response to Immunotherapy in MMR-deficient Localized Colon Cancer

  NCT05662527· Phase 2· Camilla Qvortrup· Source

• Completed

  Calcium electroporation in combination with irreversible electroporation and immunotherapy in patients with pMMR metastatic colorectal cancer

  2022-500045-25-00· Phase 2· Zealand University Hospital· Source

• Terminated

  Electroporation and Immunotherapy in Metastatic Colorectal Cancer

  NCT05609656· Phase 2· Ismail Gögenur· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Hoffmann-La Roche· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Terminated

  Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

  NCT05516498· Phase 2· AstraZeneca· Source

• Completed

  A Study in Participants With Non-cirrhotic NASH With Fibrosis

  NCT05638737· Phase 2· AstraZeneca· Source

• Completed

  Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy

  NCT05754229· Ismail Gögenur· Source

• Completed

  A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

  NCT05238675· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study of Population and Sex-specific Troponin Cutoffs for Ruling Out Acute Myocardial Infarction

  NCT05336435· Herlev Hospital· Source

• Completed

  En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer

  NCT05223491· Jørgen Bjerggaard Jensen· Source

• Completed

  A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

  NCT05093933· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Personalized Exercise Therapy and Self-management Support for Patients With Multimorbidity

  NCT04645732· University of Southern Denmark· Source

• Completed

  Thoracentesis to Alleviate Cardiac Pleural Effusion

  NCT05017753· Bispebjerg Hospital· Source

• Completed

  AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study

  NCT05028660· Elypta· Source

• Completed

  Eosinophil-guided Reduction of Inhaled Corticosteroids

  NCT04481555· Phase 4· Chronic Obstructive Pulmonary Disease Trial Network, Denmark· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source

• Completed

  When to INDuce for OverWeight? (WINDOW)

  NCT04603859· University of Aarhus· Source

• Completed

  Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

  NCT04191616· Phase 2· Amgen· Source

• Completed

  Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions

  NCT04253171· Herlev and Gentofte Hospital· Source

• Completed

  AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

  NCT04006405· Elypta· Source

• Recruiting

  Combining Active and Passive DNA Hypomethylation

  NCT03999723· Phase 2· Kirsten Grønbæk· Source

• Completed

  Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634· Phase 3· AstraZeneca· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· AGO Research GmbH· Source

• Completed

  A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

  NCT03607422· Phase 3· AbbVie· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

  NCT03235544· Phase 2· Incyte Corporation· Source

• Completed

  Quality of Life the Danish Multiple Myeloma Patients

  NCT02892383· Odense University Hospital· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· German CLL Study Group· Source

• Completed

  Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

  NCT02242942· Phase 3· Hoffmann-La Roche· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Hidradenitis suppurativa19 works · 3 trials
• Macular degeneration13 works · 4 trials
• Myeloproliferative neoplasms9 works · 2 trials
• Vitiligo5 works · 0 trials